# Molson Coors Beverage Company (TAP)

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-28  
**Report type:** Primer (steps 1–3 of 19)  
**API endpoint:** GET /api/v1/research/TAP/primer

## Business Model

---
source: coverage-next-full
ticker: TAP
step: 01
title: Business Model & Overview
retrieved: 2026-05-28
---

### Step 01 — Business Model

#### 1. Objective

Describe Molson Coors Beverage Company's business model: what it sells, to whom, through which channels, at what unit economics, and how it converts brand equity into cash.

#### 2. Approach

Used 10-K segment descriptions, IR press releases, the brand portfolio cataloged from FY2025 filings, and competitive context from the industry overview file [S1][S2][S3].

#### 3. Findings

##### What TAP Sells
A portfolio of beer and beyond-beer beverages spanning value, premium, above-premium, and non-alcoholic categories.

**Core power brands (mass-premium light beer, mass-premium lager):**
- Coors Light, Miller Lite, Coors Banquet (US)
- Molson Canadian, Coors Original (Canada)
- Carling (UK — largest-volume UK lager)
- Ožujsko (Croatia)
- Staropramen (Czech Republic / Central Europe — flagship)

**Above-premium / premium portfolio:**
- Blue Moon (US — Belgian-style wheat)
- Leinenkugel's Summer Shandy (US — seasonal)
- Madri Excepcional (UK — Spanish-style lager, now #2 UK on-premise lager by value [S3])
- Peroni Nastro Azzurro (UK distribution — note: TAP holds UK rights; Asahi owns Peroni globally)
- Pilsner Urquell (Central Europe heritage)

**Beyond Beer (FMBs, hard seltzers, energy, mixers):**
- Topo Chico Hard Seltzer (Coca-Cola JV, US)
- Simply Spiked (Coca-Cola JV, US)
- ZOA Energy (Dwayne Johnson minority-stake partnership)
- Fever-Tree US distribution (exclusive from Feb 1, 2025; 8.5% equity stake) [S4]
- Blue Run Spirits (acquired 2023; partial impairment 2025)

**Value brands:**
- Miller High Life, Keystone Light (US — value tier)

##### To Whom
- ~80% of revenue from Americas (US the dominant geography + Canada + LatAm)
- ~20% from EMEA&APAC (UK + Central/Eastern Europe primarily; small Asia presence) [S2]
- B2B customer base: independent beer distributors (US three-tier system), national grocery & C-store chains, on-premise bar/restaurant accounts. End-consumer is the eventual drinker; immediate customer is the distributor / retailer.

##### Through Which Channels
- **Off-premise (grocery, C-store, club, drug):** ~75–80% of US volume; price-elastic; competitive shelf-share battles
- **On-premise (bars, restaurants, stadiums):** ~20–25% of US volume; higher per-unit margin; brand-equity reinforcement role
- **Three-tier system (US):** Brewer → independent distributor → retailer. Distributors are TAP's economic moat partners — long contracts, geographic exclusivity, mutual investment in tap handles, signage, merchandising. The "12,000 new tap handles" cited post-Bud-Light shift is a distributor-investment metric [S3].

##### Unit Economics (FY2025 GAAP, with underlying flagged)

| Metric | FY2025 | Note |
|--------|--------|------|
| Net sales | $11,141M | -4.2% YoY [S5] |
| Gross profit | $4,275M | 38.4% margin [S5] |
| GAAP operating income | $1,675M | 15.0% margin — depressed by impairments [S5] |
| Underlying EBITDA | ~$2,400M | ~21.5% underlying EBITDA margin [S5][S6] |
| Operating cash flow | $1,784M | 16.0% OCF/sales [S5] |
| Capex | $717M | 6.4% capex/sales [S5] |
| Free cash flow | $1,068M | 9.6% FCF/sales [S5] |

##### Value-Chain Layer Map

| Layer | TAP's position | Capital intensity | Margin |
|-------|----------------|-------------------|--------|
| Raw materials (barley, hops, water, aluminum, glass, packaging) | Commodity buyer (hedges aluminum + barley) | n/a | Margin = cost-pressure absorber |
| Brewing & packaging (breweries, can/bottling lines) | Owns ~20+ major breweries globally | High — PP&E $4.96B | Conversion margin ~38–40% |
| Brand marketing / IP | Owns iconic brand IP; licenses some (Peroni UK from Asahi; Carling licensed historically) | Asset-light P&L line | High contribution margin |
| Distribution (three-tier US) | Partners with independent distributors (does not own US distribution) | Low — distributor invests | Embedded as gross-margin haircut |
| Retail / On-premise | Sells to retailers; partners with on-premise accounts | n/a | n/a |

##### How It Makes Money
- **Volume × Price × Mix** model. Per-hectoliter net sales revenue (NSR/HL) is the master KPI. Volume declines have been offset for several years by pricing + mix shift (above-premium gaining mix share within a contracting overall pie).
- **Net pricing 2025:** in the +2% to +4% range across regions, with Americas +3–4% and EMEA&APAC +4–5% (constant currency) [S6]. Underlying EBITDA margin held ~21–22% on a 4% decline in net sales — pricing discipline.
- **Beyond Beer** is partnership-led and capital-light vs. building from scratch. Coca-Cola JV provides marketing reach for Topo Chico + Simply Spiked. Fever-Tree gives TAP the US non-alc-mixer beachhead at minority equity cost.

#### 4. Risks & Counter-Evidence

- **Distributor concentration risk:** TAP depends on independent distributors. If a major distributor pivots commitment, share losses follow rapidly. The Bud-Light story cuts both ways — TAP captured share via distributor-channel choice, and could lose it via the same mechanism.
- **Brand fade risk on light beer:** Coors Light and Miller Lite are in a sub-category (mass-premium American light) facing the worst demographic + GLP-1 headwinds. Even with share gains, the addressable pie is shrinking.
- **Beyond Beer is small:** Despite headlines, beyond beer is a small fraction of revenue. Blue Run Spirits already partially impaired ($75.3M in Q3 2025). Topo Chico Hard Seltzer has not become the share leader many expected.

#### 5. Decision / What I'm doing differently

Treat TAP as **a brewer first, beyond-beer aspirant second.** ~95% of the equity value comes from the core beer P&L. Beyond-beer is option value — meaningful for the multi-year story but not material to base-case 2026–2028 forecasts.

#### 6. Open Questions

1. Will Madri-style above-premium creations work in the US, or is it a UK-specific phenomenon? Step 03 examines revenue mix evolution.
2. What is the actual unit-economics of the Coca-Cola JV — is TAP economics or marketing-and-distribution-only? Press releases not fully transparent.

#### 7. Source Index

- [S1] `TAP_financials/sec_filings/filing_inventory.md` — FY2025 10-K
- [S2] `TAP_financials/industry/competitive_landscape.md`
- [S3] Fox Business — "Coors Light, Miller Lite combined sales now 50% bigger than Bud Light"
- [S4] BusinessWire — Fever-Tree partnership PR (Jan 30, 2025)
- [S5] `TAP_financials/xbrl/xbrl_summary.md`
- [S6] Molson Coors IR — Q4 2025 / FY2025 earnings release (Feb 18, 2026)

## Financial Snapshot

---
source: coverage-next-full
ticker: TAP
step: 04
title: Financial Snapshot & Adversarial Research Sweep
retrieved: 2026-05-28
---

### Step 04 — Financial Snapshot

#### 1. Objective

Assess the quality of TAP's reported financials, identify accounting / one-time / impairment adjustments, and run the **Adversarial Research Sweep** for short-seller reports, investigations, lawsuits, and quality-of-earnings flags.

#### 2. Approach

Cross-referenced the cached XBRL summary [S1], reviewed FY2025 impairment disclosures [S2], scanned for litigation / short reports / investigations [S3][S4], and benchmarked GAAP-vs-underlying reconciliation against company-disclosed methodology [S2].

#### 3. Findings

##### Statement Quality — GAAP vs Underlying

The biggest single quality issue is the **FY2025 impairment package**: $3,645.7M Americas goodwill + $198.6M Staropramen brand + $75.3M Blue Run Spirits = $3,919.6M aggregate non-cash charges [S2]. All flow through GAAP operating income and to the GAAP net loss of $2,140M.

**Underlying basis** (company's preferred framing): excludes these impairments + restructuring charges + mark-to-market on commodity hedges + special items. Underlying EBITDA FY2025 ~$2.4B, underlying EPS ~$5.40 (consensus tracking estimate).

**Quality verdict:** GAAP loss is a true non-cash hit — equity book value reduced by ~$3.9B — but underlying cash-generative business is intact. For analytical purposes, use underlying figures for run-rate earnings power; use GAAP for full disclosure / equity-value-book-discipline check.

##### Cash Flow Conversion

| Year | OCF / Revenue | FCF / Revenue | OCF / EBITDA (underlying) | Comment |
|------|---------------|---------------|---------------------------|---------|
| 2025 | 16.0% | 9.6% | ~74% | Strong; little to flag |
| 2024 | 16.4% | 10.6% | ~77% | |
| 2023 | 17.8% | 12.0% | ~91% | Best year recent |
| 2022 | 14.0% | 7.9% | ~83% | |
| 2021 | 15.3% | 10.2% | ~68% | |

[S1]

Cash conversion is consistently in the 70–80%+ range of underlying EBITDA — high-quality, well-correlated with reported underlying earnings.

##### Working Capital Discipline

| YE | Receivables (% of revenue) | Inventory (% of revenue) | Payables (% of revenue) | Net working capital position |
|----|---------------------------|--------------------------|-------------------------|------------------------------|
| 2025 | 8.0% | 6.4% | 17.8% | Negative (favorable, ~3.4% benefit) |
| 2024 | 7.3% | 6.3% | 17.4% | Negative |
| 2023 | 7.5% | 6.9% | 18.2% | Negative |
| 2022 | 8.1% | 7.4% | 20.8% | Negative |

[S1]

TAP runs **negative working capital** (payables > receivables + inventory) — typical for CPG with distributor-led downstream financing. No red flags; payables-driven cash management is stable.

##### Capex Discipline

| Year | Capex ($M) | Capex / Revenue | Capex / D&A | Note |
|------|-----------|-----------------|-------------|------|
| 2025 | 717 | 6.4% | ~95% (D&A ~$760M) | Near maintenance |
| 2024 | 674 | 5.8% | ~90% | |
| 2023 | 672 | 5.7% | ~92% | |
| 2022 | 661 | 6.2% | ~95% | |

Capex roughly tracks D&A — no aggressive growth-investment cycle; mostly maintenance + can-line modernization. 2026 guide $650M (also near D&A).

##### Capital Structure Quality

- Long-term debt $3.81B (2025) — down from $6.06B in 2024 (refinancing / paydown / reclassification effect; some moved to current liabilities — current liab jumped to $5.31B from $3.05B reflecting near-term maturities)
- Net debt $5.4B (per company), 2.3x underlying EBITDA — below stated target of <2.5x [S2]
- Investment-grade credit ratings (BBB / Baa2 area)
- Manageable maturity ladder

##### Adversarial Research Sweep

**Short-seller reports:** No active major short-seller report on TAP identified [S3][S4]. Hindenburg, Muddy Waters, Citron, Spruce Point: no published TAP coverage in recent years.

**Litigation:** Standard product-liability tail risk + ordinary-course commercial disputes; no material outstanding litigation flagged in FY2025 10-K beyond routine.

**Regulatory investigations:** None disclosed [S2][S3].

**Quality-of-earnings flags:** 
1. **Goodwill impairment trigger:** The $3.65B Americas goodwill impairment in Q3 2025 was the principal QoE event. Triggered by softer-than-expected current-year results + lower long-term forecasts post-impairment-test [S2]. The market read this as honest reset of accounting carrying value vs. underlying operations.
2. **Blue Run Spirits impairment** ($75.3M, Q3 2025) — acquired 2023; growth target missed. Small relative to the package; signal: M&A discipline imperfect.
3. **Staropramen partial impairment** ($198.6M, Q3 2025) — softer CEE volumes; brand-equity reset.

**Cash-EPS bridge:** Underlying EPS ~$5.40 vs underlying FCF/share ~$5.40 (FCF $1,068M ÷ ~199M shares). They reconcile cleanly. No "earnings-without-cash" issue.

**Revenue recognition / channel stuffing:** Beer industry is volume-disclosed (HL shipped) — relatively hard to manipulate via revenue-recognition tricks. Distributor-channel inventory is monitored; TAP has not been flagged for channel-stuffing.

**Pension / OPEB:** Minor relative to size; no acute funding issue disclosed.

**Hedge accounting:** TAP uses commodity hedges (aluminum, barley, natural gas) and FX hedges. 2025 underlying-vs-GAAP reconciliation includes mark-to-market on non-designated hedges. Standard practice; not a red flag.

##### Adjusted Free Cash Flow Quality

Underlying FCF (using underlying definitions): roughly $1.0–1.1B annually 2024–2026. 2026 guide $1.1B ± 10% [S5]. This is the truest measure of capacity to fund dividend + buyback + de-leveraging.

#### 4. Risks & Counter-Evidence

- **Underlying-vs-GAAP gap is large in 2025** — management has flexibility in defining "underlying" — analyst should track quarter-by-quarter what adjustments are added and ensure they're truly non-recurring.
- **Brand impairment risk continues:** If US volumes decelerate further, ANOTHER goodwill impairment leg is possible (Americas goodwill now down to $1.95B vs $5.6B at YE2024; smaller cushion but not gone).
- **Tax rate:** 22–24% underlying ETR is consistent; no aggressive tax-planning red flag.

#### 5. Decision / What I'm doing differently

Use **underlying basis** for forward modeling. Apply a conservative haircut to underlying EBITDA forecast (10–15%) in the bear case to account for the possibility of further impairments or unfavorable adjustment reclassifications. GAAP results in 2025 are not predictive of run-rate earnings power.

#### 6. Open Questions

1. Will Q3 2026 (impairment-test annual cycle) trigger another non-cash charge? Watch volumes and pricing through H1 2026.
2. How does the $450M cost program show up in adjusted vs GAAP — will restructuring charges be excluded from underlying (the typical "add-back-then-take-credit" pattern)?

#### 7. Source Index

- [S1] `TAP_financials/xbrl/xbrl_summary.md`
- [S2] Molson Coors Q3 2025 10-Q and 8-K; FY2025 10-K
- [S3] Web search — short-seller report scan (no major TAP coverage from Hindenburg/Muddy Waters/Citron/Spruce Point in trailing 3 years)
- [S4] WSJ / FT / Reuters litigation databases — no material flagged
- [S5] Molson Coors 2026 guidance — Feb 18, 2026 8-K

## Recent Catalysts

---
source: coverage-next-full
ticker: TAP
step: 12
title: Analyst Debate — Bull vs Bear
retrieved: 2026-05-28
---

### Step 12 — Analyst Debate (Bull vs Bear)

**Note: transcripts were not loaded (coverage-next-full path).** The debate framing is reconstructed from filings, press releases, prepared-remarks summaries in third-party coverage, consensus notes (Barclays UW $43, UBS $45, consensus PT $51.47), and recent news flow rather than from listening to management Q&A.

#### 1. Objective

Frame the active investment debate on TAP and resolve to a Bull Case + Bear Case structure that feeds `/complete-coverage` Step 15 (scenarios) and the public `/stocks/{ticker}` page.

#### 2. Approach

Distilled the multi-source evidence package built across Steps 00–11 into the two competing narratives institutional investors actually argue today.

#### 3. The Debate Structure

The active argument is **NOT** "Bud Light windfall persists" (that's historical context now). The live debate is:

**Bulls argue:** TAP is a deep-value capital-return story. Trading at 5.7x EV/EBITDA, 8.9x forward P/E, with a 4.7% dividend yield + ~4.6% buyback yield = ~9% shareholder yield. Underlying earnings power is stable around $5.40 EPS even in a category-decline environment; the $450M cost program adds upside; the Bud-Light-era share gains are durable; the Q1 2026 beat shows the cost program is flowing through. At sub-$45/share, you're getting paid a 9% yield to wait while management compounds underlying earnings flat-to-up.

**Bears argue:** The category is in structural decline that capital return + cost cuts cannot offset. US beer volumes -6% in 2025; -6 to -9% guided for Q2 2026; GLP-1 + cannabis + spirits substitution are accelerating; the Q3 2025 $3.92B impairment was a forced acknowledgment that prior forecasts were too optimistic; residual $1.95B Americas goodwill can be impaired further; 96% FCF payout leaves no buffer; ROIC is barely above WACC; family-controlled dual-class governance limits take-out optionality. Forward EPS guide of -11 to -15% YoY is the floor, not the ceiling. At 5.7x EV/EBITDA there's no "cheap" cushion if the next leg of category decline is -8% rather than -4%.

#### 4. Bull Case — 3 bullets

- **9%+ Total Shareholder Yield Is the Compounding Engine.** Combined ~4.7% dividend yield + ~4.6% buyback yield = ~9% combined shareholder yield, fully funded by $1.0–1.1B run-rate FCF. With ~5% annual share-count reduction at current pace (~$650M/yr buyback at sub-$50 share price), per-share underlying EPS grows ~5% annually even at flat underlying earnings. Forward total return math (9% yield + 5% EPS growth from buybacks) of ~14% is achievable with no underlying earnings growth — the **base case for the equity does not require the category to recover, only to stabilize.** [S1][S2]

- **The $450M Cost Program + Premiumization Provides Operating Leverage Upside.** The Feb 2026 announced three-year cost program ($450M cumulative, beginning H2 2026) targets supply-chain productivity, organizational optimization, and plant rationalization (including a UK brewery closure). If even ~$150M flows to net underlying EBITDA by 2028, that's ~6% margin improvement on a flat top line. Concurrently, above-premium portfolio (Madri +15% Q3 2025, Peroni +25% Q3 2025) is climbing toward management's ~33% revenue-mix target from ~27% today. Both together = a multi-year operating-margin expansion runway that current 5.7x EV/EBITDA does not price in. **Q1 2026 EPS beat ($0.62 vs $0.38 consensus, +24% YoY) on -2.9% volume is the early proof point that the program is working.** [S3][S4]

- **Bud-Light-Era Share Gains Are Durable + Modelo Risk Is Already Priced.** Coors Light + Miller Lite combined US retail dollars are now ~50% bigger than Bud Light, with 80%+ retention of post-controversy share gains [S5]. CEO Goyal (since Oct 2025) inherited a structurally improved US share position and is doubling down with premium-portfolio investment. While Modelo (STZ) continues to take category-level share, TAP trades at ~5.7x EV/EBITDA vs STZ at ~14x — **a ~60% discount that prices in the structural disadvantage and then some**. Mean reversion to even ~7x EV/EBITDA (still well below STZ) implies ~30–40% upside on multiple alone, on top of the 9% shareholder yield. [S6]

#### 5. Bear Case — 3 bullets

- **The Category Is in Structural Decline, Not a Cyclical Trough.** US beer volumes -6% in 2025 [S7]; Q2 2026 US financial volumes guided -6 to -9% YoY [S3]; cannabis beverages projected $2.8B by 2028 at ~17% CAGR [S8]; ~12.5% of US adults have used GLP-1s, with ~43% of cutters reducing beer [S9]; younger cohorts drink materially less than prior generations. There is no plausible scenario in which US beer volumes return to growth this decade. **Pricing power (+2–3% annually) is partially exhausted** — Q3 2025 impairment was the forced GAAP acknowledgment that prior forecasts were too optimistic, and the remaining $1.95B Americas goodwill is at further risk if 2026 volume tracks the -6 to -9% guide. Even a "stable" thesis assumes -3 to -5% perpetual category decline, with TAP's mass-premium light beer brands in the worst-affected sub-segment.

- **2026 Profit Warning Is the Floor, Not the Ceiling — Underlying EPS -11% to -15% Guided.** Feb 18, 2026 guidance: underlying IBT -15% to -18%, underlying EPS -11% to -15% [S3]. Driver mix is unfavorable — aluminum / Midwest Premium tariff inflation is a 100–200 bps gross margin hit, restructuring charges flow through 2026–2027, interest expense steps up on refinancings. Cost program savings are back-half-2026-loaded and may under-deliver (history of CPG cost programs is mixed). If volumes deteriorate beyond guide, the EPS trajectory becomes -15 to -20%, not -11 to -15%, and dividend coverage stretches uncomfortably. **96% FCF payout ratio leaves no margin of error** — a $200M shortfall in FCF forces a moderation of buyback pace, removing the share-count tailwind that anchors the bull EPS math.

- **Governance Limits Optionality, Multiple Cannot Re-Rate Without a Catalyst.** Family-controlled dual-class voting trust (Pentland + Coors) means activist pressure, take-out scenarios, and strategic split-ups are essentially off the table. Berkshire Hathaway does NOT hold TAP per Q1 2026 13F-HR [S10] — removes a common "smart-money-buying" narrative. New CEO Goyal is an internal candidate (24-year tenure) signaling continuity, not strategic reset. Cheap stays cheap absent a re-rating catalyst — and the catalyst path is narrow: another category leg lower could compress the multiple further (5.7x to 4.5x), while a stabilization narrative may take 4–6 quarters of data to credentialize with the market. The 9% shareholder yield is real but **could be a value trap if the underlying earnings power steps down by 15–20% from here on top of further multiple compression.**

#### 6. Resolution / What I'm doing differently

The two cases are roughly symmetric around the current ~$42 price. The Bull case implies $55–65 fair value (1.3–1.5x current); the Bear case implies $30–35 fair value (0.7–0.8x current). The **probability-weighted view** is **slightly bullish on a 12–24 month horizon** (60% bull / 40% bear weighting, given Q1 2026 beat + cost-program credibility), with the **9% yield providing material downside protection** in the bear case.

**Position-sizing implication** (developed in Step 18): **small-to-medium tactical/yield position, NOT a core compounder.** Right-sized for ~3–5% portfolio weight, with the option to add on category-stabilization data points (Q2 + Q3 2026 prints) or trim on accelerated category decline.

#### 7. Open Questions

1. Does Q2 2026 (Jul–Aug 2026) print confirm Q1 momentum, or revert to the Q1–Q3 2025 weakness?
2. Does the aluminum / Midwest Premium pressure ease into 2027, allowing margin recovery?
3. Does a Bud Light recovery dent TAP's retained share gains, or does Modelo continue taking from both?

#### 8. Source Index

- [S1] `TAP_financials/xbrl/xbrl_summary.md` — capital return data
- [S2] `TAP_financials/other/stockanalysis_summary.md` — dividend yield, EV/EBITDA
- [S3] Molson Coors IR — Q4 2025 / FY2025 release (Feb 18, 2026); 2026 guidance
- [S4] Molson Coors Q1 2026 release (Apr 30, 2026); StockStory Q1 CY2026 coverage
- [S5] Fox Business — Coors Light + Miller Lite vs Bud Light
- [S6] `TAP_peer_universe.md` — multiples vs peers
- [S7] thedrinksbusiness.com — IWSR US alcohol -5% 2025
- [S8] mgmagazine.com — Cannabis Drinks Surge
- [S9] EY — GLP-1 alcohol market dynamics
- [S10] 13Radar / Seeking Alpha — Berkshire Q1 2026 13F-HR (TAP not held)

## Full Research Available

This primer covers steps 1–3 of 19. The full deep dive (moat analysis, DCF, bull/bear,
management quality, earnings transcript analysis) is available via:

- Investment memo: /memo/tap
- Full research API: GET /api/v1/research/TAP/memo
- Coverage universe: /stocks